IN-PART
Inpart is a UK-based B2B SaaS platform that unifies R&D partnering for life sciences organizations, offering partner discovery, deal management, and a harmonizing data engine to more than 500 enterprise clients, including 70% of the top 50 global pharmaceutical companies.
- Company typePrivate
- Founded2014
- HeadquartersSheffield, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What IN-PART does
IN-PART (legal name Inpart) is a UK-based, private B2B SaaS company founded in 2014 in Sheffield that operates an end-to-end cloud-based platform for R&D partnering in the life sciences. Originally built to match university technologies with senior R&D decision-makers, the platform has expanded to serve 500+ life sciences clients, including 70% of the top 50 global pharmaceutical companies, with named customers such as Pfizer, Novo Nordisk, Eli Lilly, Novartis, UCB, and ENGIE. Its core offering is structured as a hub-and-module architecture: the Inpart Platform unifies the workflow, Connect handles partner discovery and personalized landscaping across a global network of science, Deal centralizes partnership management and cross-functional dealmaking workflows, and an underlying Data Engine standardizes unstructured taxonomies and fragmented data into a comparable, AI-ready single source of truth.
The company's revenue model is enterprise SaaS subscription, sold on a quote-based, annual cadence tailored to organization size and needs, with both direct enterprise field sales and a self-serve onboarding path for initial evaluation. Customers span multiple horizontal functions — Open Innovation, Research & Development, Search & Evaluation, Business Development, Due Diligence, and Alliance Management — covering the full partnering lifecycle from scouting through post-deal alliance tracking. The platform holds ISO 27001 certification and is GDPR-compliant, positioning it for regulated enterprise procurement.
IN-PART has disclosed approximately $1.65M in cumulative equity funding across three known rounds (Northern Stars 2015, Mercia Asset Management 2016, Northern Powerhouse Investment Fund 2019), and is led by co-founder and co-CEO Patrick Speedie alongside co-founder and director Robin Knight. Reported client outcomes include up to $4.8M in annual cost savings, more than 24,000 hours saved per year, up to 3x faster evaluations, and up to $50M in added portfolio value across the partnering lifecycle. The company has a content partnership with Labiotech.eu and operates a direct plus product-led-growth distribution mix targeting global enterprise buyers.
IN-PART firmographics
Firmographics- Name
- IN-PART
- Legal name
- Inpart
- Website
- https://in-part.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inpart is a UK-based B2B SaaS platform that unifies R&D partnering for life sciences organizations, offering partner discovery, deal management, and a harmonizing data engine to more than 500 enterprise clients, including 70% of the top 50 global pharmaceutical companies.
- Ownership category
- akta.pro rank
IN-PART industry classification
Industry- Product category
- R&D Partnering Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210), Computer Systems Design Services (541512)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Enterprise Work Management & Collaborative Workflow Platforms (HDAEAHAI)
- akta.pro secondary industries
- Data Platform (Unified Data & Analytics) Suites (HDAEABAD), Connector/Adapter Frameworks & Integration Runtimes (HDAEACAJ)
Keywords
Where IN-PART is headquartered
LocationHeadquarters
- HQ city
- Sheffield
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
IN-PART business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Platform Subscription: Enterprise SaaS subscription model for access to the full Inpart platform including Connect (discovery) and Deal (management) products. Pricing is quote-based and customized to organization size and needs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform subscription |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
IN-PART product offering
Product offeringCore offering
IN-PART operates an end-to-end cloud-based SaaS platform that helps life sciences organizations discover external R&D partners, manage partnership pipelines and deal workflows, and run alliance management. The platform consists of the core Inpart Platform with two named product modules, Connect for partner discovery and Deal for partnership/deal management, supported by a proprietary Data Engine that harmonizes fragmented taxonomies and unstructured data into a single source of truth.
Product overview
Inpart is a B2B SaaS platform for R&D partnering, built as an end-to-end platform with modular components. The core Inpart Platform serves as the central hub, supported by two named product modules: Connect (for partner discovery and opportunity sourcing) and Deal (for partnership management and dealmaking). The Data Engine capability underpins the platform by harmonizing data across the system. The platform also includes solution modules for Open Innovation, Research & Development, Search & Evaluation, Business Development, Due Diligence, and Alliance Management, covering the full partnering lifecycle from scouting to alliance management.
Differentiator
Problem solved
Functional benefit
Products and services
- Inpart Platform End-to-end R&D partnering platform that unifies data, insights, and teams to help organizations discover, manage, and deliver high-impact innovation faster through connected workflows.
- Connect Partner discovery product enabling users to uncover new partners and opportunities across a global network of science and personalized landscaping.
- Deal Partnership management product that unifies scattered information and cross-functional workflows in one secure, connected system built for collaboration and dealmaking.
Quantifiable outcome
- Up to $4.8M saved annually through automated workflows, simplified reporting, and increased win ratio
- +3 more outcomes
Companies that use IN-PART
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles2 records
IN-PART technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IN-PART partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Labiotech.euminorContent partnership with Labiotech.eu, a leading life sciences news and insights platform, for industry reach and thought leadership distribution.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
IN-PART competitors and assessment
Company assessmentBroad incumbents
- Veeva Systems: Dominant life-sciences cloud platform offering Vault, CRM, and deal/alliance management. Comparable because it serves the same enterprise pharma customers and provides overlapping capabilities for managing R&D partnerships and alliances, though as part of a much broader regulated-industry portfolio.
- Citeline (Informa Pharma Intelligence): Drug development and clinical trial intelligence platform used by pharma for pipeline and partnering decisions. Overlaps with IN-PART in providing intelligence that supports R&D partnering and external innovation strategy.
- Clarivate: Provides life-sciences and IP intelligence, including drug pipeline, patent, and competitive intelligence offerings. Comparable as an enterprise data/intelligence backbone for pharma partnering and R&D strategy.
- Salesforce: Enterprise CRM and workflow platform with partner relationship management capabilities. Comparable as the broad incumbent whose platforms pharma enterprises use to manage alliances, partnerships, and deal pipelines, with potential to expand deeper into R&D-specific workflows.
- IQVIA: Global life-sciences analytics and services firm offering intelligence, R&D solutions, and commercial platforms. Comparable as a broad incumbent serving the same enterprise pharma customers with overlapping R&D and partnering intelligence capabilities.
Direct peers
- DealForma: Partnering intelligence platform for biopharma deal-making, sourcing, and competitive intelligence. Closely comparable to IN-PART's Connect product in enabling partner discovery and pipeline/portfolio evaluation for life sciences business development teams.
- BioCentury: Biopharma intelligence and partnering platform serving business development and corporate strategy teams. Directly comparable in providing partnering intelligence, deal coverage, and analysis used by the same enterprise buyer personas as IN-PART.
- EvaluatePharma: Pharma industry intelligence and forecasting platform covering pipelines, deals, and company performance. Comparable in providing data-driven intelligence that supports the same partnering and portfolio evaluation use cases IN-PART targets.
Emerging players
- PatSnap: Innovation intelligence platform using AI to surface R&D, patent, and market insights. Comparable to IN-PART's data harmonization and discovery capabilities, particularly for R&D teams evaluating external opportunities.
- Benchling: Cloud R&D platform for life sciences covering experimental data, workflows, and collaboration. Comparable as an enterprise platform serving biopharma R&D teams, with overlapping workflow and data harmonization themes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
IN-PART social profiles
Digital presenceIN-PART compliance and trust
Trust signalCompliance2 records
IN-PART financial estimates
Financial estimateRevenue estimate
Valuation estimate
IN-PART leadership team
Management profileNumber of profiles
Profiles2 records
IN-PART funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IN-PART M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IN-PART
What does IN-PART do?
IN-PART operates an end-to-end cloud-based SaaS platform that helps life sciences organizations discover external R&D partners, manage partnership pipelines and deal workflows, and run alliance management. The platform consists of the core Inpart Platform with two named product modules, Connect for partner discovery and Deal for partnership/deal management, supported by a proprietary Data Engine that harmonizes fragmented taxonomies and unstructured data into a single source of truth.
Is IN-PART a public or private company?
IN-PART is a private company. It is classified as venture growth investor backed and is currently operating.
When was IN-PART founded?
IN-PART was founded in 2014. It employs 11 to 50 people.
Where is IN-PART based?
IN-PART is headquartered in Sheffield, United Kingdom, in the Europe region.
How does IN-PART make money?
One revenue line is on record: platform Subscription.
Who are IN-PART's main competitors?
Broad incumbents on record are Veeva Systems, Citeline (Informa Pharma Intelligence), Clarivate, Salesforce and IQVIA. Direct peers are DealForma, BioCentury and EvaluatePharma. Emerging players are PatSnap and Benchling.
Does IN-PART have an API?
No public API is recorded for IN-PART.
What industry is IN-PART in?
IN-PART's product category is R&D Partnering Software. Its primary akta.pro industry code is HDAEAHAI, Enterprise Work Management & Collaborative Workflow Platforms, with a secondary code of HDAEABAD, Data Platform (Unified Data & Analytics) Suites. Its NAICS code is 518210 and its SIC code is 7372.